Top Losers

  Essendant Inc (NASDAQ: ESND) shares declined 34.2 percent to $21.34. Essendant posted Q2 adjusted earnings of $0.55 per share on revenue of $1.35 billion. Monotype Imaging Holdings Inc. (NASDAQ: TYPE) shares fell 27.8 percent to $18.00 as the company reported the intent to buy...

  Zafgen Inc (NASDAQ: ZFGN) shares tumbled 50.2 percent to $3.36 after the company reported that it has suspended the development of its obesity drug Beloranib. Evoke Pharma Inc (NASDAQ: EVOK) shares dipped 16 percent to $2.08. Evoke Pharma reported a $4.5 million ATM offering....

  Super Micro Computer, Inc. (NASDAQ: SMCI) shares dropped 28.2 percent to $18.91 after the company lowered its Q4 forecast and announced a $100 million buyback plan. SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) shares dipped 20.7 percent to $10.52. SciClone Pharma reported that it...

  Evoke Pharma Inc (NASDAQ: EVOK) shares fell 71.5 percent to $3.06 after the company revealed that its topline results from its Phase 3 clinical trial of EVK-001 failed to achieve its primary endpoint of symptom improvement at the end of four weeks in female patients with symptomatic...

  CytRx Corporation (NASDAQ: CYTR) shares dropped 33.2 percent to $0.601. CytRx reported that it has priced its 28.6 million share offering at $0.70 per share. Fairmount Santrol Holdings Inc (NYSE: FMSA) shares fell 21.5 percent to $6.37 after the company reported weak preliminary...

  Rennova Health Inc (NASDAQ: RNVA) shares dipped 48 percent to $0.281. Rennova Health reported the pricing of its $8,600,000 public offering. China Metro Rural Holdings Ltd (NYSE: CNR) shares declined 18.4 percent to $1.47. Brocade Communications Systems, Inc. (NASDAQ: BRCD)...

  Bonanza Creek Energy Inc (NYSE: BCEI) shares dropped 40.8 percent to $1.35. Bonanza Creek Energy has retained Perella Weinberg Partners to advise the company and assist in analyzing and evaluating financial and transactional alternatives, including restructuring options. Avinger...

  CytRx Corporation (NASDAQ: CYTR) shares dropped 62.6 percent to $0.940 after the company reported initial results of Phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcoma. Escalon Medical Corp. (NASDAQ: ESMC) shares declined 25.7 percent to $0.751. NF...

  Vicon Industries, Inc. (NYSE: VII) shares declined 19 percent to $0.850. Echo Therapeutics Inc (NASDAQ: ECTE) shares dipped 15.6 percent to $1.51. Echo Therapeutics’ common stock will be suspended on Nasdaq at the opening of business on July 12, 2016. The company’s...

  Juno Therapeutics Inc (NASDAQ: JUNO) shares dipped 31.3 percent to $28.04 after the company announced JCAR015's Phase 2 trial was put on hold after two patients died last week. T2 Biosystems Inc (NASDAQ: TTOO) shares declined 20 percent to $6.09. T2 Biosystems extended timeline...

  Great Panther Silver Ltd (NYSE: GPL) shares dipped 17 percent to $1.54 after the company reported a deal to sell 12.5 million shares at $1.60 per share. Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) shares fell 12.1 percent to $4.01. First Solar, Inc. (NASDAQ: FSLR) shares declined...

  GlobeImmune Inc (NASDAQ: GBIM) shares tumbled 40.4 percent to $1.07 after the company reported delisting and deregistration of common stock. Eagle Bulk Shipping Inc (NASDAQ: EGLE) shares fell 16.1 percent to $0.365. Eagle Bulk Shipping reported proceeds of $85 million in sale of...

  Amedica Corporation (NASDAQ: AMDA) shares declined 30 percent to $0.930. Amedica priced its $11 million offering at $1 per unit. XBiotech Inc (NASDAQ: XBIT) shares fell 27.83 percent to $17.97 after the company reported that it has presented results from Phase 3 data for Xilonix...

  InspireMD Inc (NYSE: NSPR) shares tumbled 19 percent to $0.259. InspireMD reported the pricing of public offering of around $14.6 million. Franklin Covey Co. (NYSE: FC) shares slipped 10.7 percent to $13.70 as the company posted weaker-than-expected results for its third quarter on...

  Galena Biopharma Inc (NASDAQ: GALE) shares dropped 85 percent to $0.310 after the company reported the discontinuation of Phase 3 PRESENT clinical trial due to futility of study. Lipocine Inc (NASDAQ: LPCN) shares tumbled 51.8 percent to $3.03 following announcement of a Complete...